RPCEC00000133
Completed
Phase 1
Safety and immunogenicity of Heptavalent Conjugate Vaccine against Pneumococcal in healthy adults. Phase I.
Biomolecular Chemistry Center (CQB)0 sites40 target enrollmentJuly 20, 2012
ConditionsPneumococcal infection.
Overview
- Phase
- Phase 1
- Intervention
- Not specified
- Conditions
- Pneumococcal infection.
- Sponsor
- Biomolecular Chemistry Center (CQB)
- Enrollment
- 40
- Status
- Completed
- Last Updated
- last year
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •1\. Subjects aged between 18 and 35 (including the limit ages) 2\. General, regional and specific physical examination without any alteration. 3\. Vital signs within the following limits: \- Sistolic Blood Pressure \< 140 mmHg \- Diastolic Blood Pressure \< 90 mmHg \- Heart rate80 ± 20 per minute \- Respiratory rate16 ± 4 per minute \- Temperature\< 37 0C 4\. Subject with hemoglobin rate above 12\.5 g/L and other laboratory findings within the range of reference values. 5\. Body Mass Index (BMI) between 18\.5 and 29\.9 (including the limits). 6\. Subjects who express their consent to participate in the study written.
Exclusion Criteria
- •1\. Chronic diseases such as Asthma, Chronic Obstructive Pulmonary Disease (COPD), Ischemic Heart Disease, High Blood Pressure (hypertension), Diabetes mellitus (DM), thyroid disease, Epilepsy, neuropathies or diseases of the haemolymphopoietic system. 2\. Immunosuppresive diseases, either congenital or acquired. 3\. Fever or acute infection within ten (10\) days prior to vaccination or upon the shot. 4\. Severe allergic disease or immune system diseases. 5\. Renal and / or hepatic failure. 6\. Hypersensitivity to thimerosal or any of the other components of the formulation. 7\. Mentally handicapped 8\. Convulsive encephalopathies 9\. Immunostimulatory or immunosuppressive therapy, blood products or other vaccinations in a period of 2 months 10\. Subject with a history of previous vaccination against Streptococcus pneumoniae 11\. Alcoholism.
Outcomes
Primary Outcomes
Not specified
Similar Trials
Completed
Phase 1
Heptavalent Conjugate Vaccine against Pneumococcal (VCN7-T) in healthy infants and children.Pneumococcal infectionRPCEC00000173Biomolecular Chemistry Center (CQB)
Completed
Phase 2
Heptavalent Conjugate Vaccine against Pneumococcal (VCN7-T) in healthy children.Pneumococcal infectionRPCEC00000182Biomolecular Chemistry Center (CQB)1,140
Recruiting
Phase 1
Safety and immunogenicity of a travalent bioconjugate vaccine Shigella -: A phase1/2 randomized controlled and aged escending study including dose finding in 9 month old infantsShigelossisPACTR202105845422919immaTech Biologics AG592
Recruiting
Phase 4
Safety and Immunogenicity of heterologous or homologous booster after complete vaccination against COVID-19.Covid19D012141RBR-5y9y7p7Secretaria Municipal de Saúde do Rio de Janeiro
Completed
N/A
Safety and immunogenicity of meningococcus C conjugate vaccineMeningococcus C diseaseInfections and InfestationsMeningococcal infectionISRCTN37262487Bio-Manguinhos/Fiocruz (Brazil)60